In a prostate cancer trial, enzalutamide plus pembrolizumab was associated with increased PD-L1 expression in tumor and dendritic cells, and increased PD-1-positive in circulating T-cells (Bishop et al., 2015; Graff et al., 2016). Here, CD274 is linked to prostate carcinoma.